Duodopa (levodopa/carbidopa intraduodenal gel infusion) / AbbVie - LARVOL DELTA

Endoscopic Outcomes of PEG-J for Levodopa-Carbidopa Intestinal Gel Infusion in Advanced Parkinsonâs Disease: A Large Single Center Retrospective Experience (ACG 2026) - "Eighty-one patients were included; mean age was 57.6 ± 11.8 years and 49 patients (60.5%) were male. Initial PEG-J placement was technically successful in all patients (100%). Over a median follow-up of 983 days, 271 endoscopic procedures were performed, of which 190 (70.1%) were repeat interventions."

Metastases • Retrospective data • CNS Disorders • Movement Disorders • Parkinson's Disease

Jejunal Bezoar From a Knotted PEG-J Tube Causing Small Bowel Obstruction During LCIG Therapy (ACG 2026) - "Contrast-enhanced CT scan of the abdomen reveals a hypodense mass with internal air locules, consistent with a bezoar, located in the jejunum at the distal tip of the jejunostomy (J-) tube. The gastric fixation plate is noted to be in a stable, appropriate position."

CNS Disorders • Movement Disorders • Parkinson's Disease

Switch from LCIG to LECIG in advanced Parkinson’s Disease: Real World Outcomes from a Single Centre (MDS Congress 2026) - No abstract available

Clinical • Metastases • Real-world • Real-world evidence • CNS Disorders • Movement Disorders • Parkinson's Disease

Continuous Subcutaneous Foslevodopa/Foscarbidopa After Deep Brain Stimulation or Levodopa–Carbidopa Intestinal Gel: A Case Series in Advanced Parkinson's Disease (MDS Congress 2026) - No abstract available

Clinical • Metastases • CNS Disorders • Movement Disorders • Parkinson's Disease

Levodopa-Carbidopa Intestinal Gel Infusion Therapy in Advanced Parkinson’s Disease: Extension Study of Long-term outcomes of Single Centre experience (MDS Congress 2026) - No abstract available

Clinical • Metastases • CNS Disorders • Movement Disorders • Parkinson's Disease

Impact of Uncontrolled Motor Fluctuations in Parkinson's Disease: Real-World Insights from the PROSPECT Observational Study. (PubMed, Adv Ther) - "Despite device-aided therapy eligibility, most patients with PD remained exclusively on oral medications. Device-aided therapy initiation was associated with improved motor symptoms, while those who remained on oral medications showed no meaningful change."

Journal • Observational data • Real-world evidence • CNS Disorders • Movement Disorders • Parkinson's Disease

Reply to the Letter on: "Electrophysiological and Biochemical Evaluations of Neuropathy Risk in Oral Levodopa versus Levodopa/Carbidopa Intestinal Gel Treatment". (PubMed, Arq Neuropsiquiatr) - No abstract available

Journal • Pain

Comment on "Electrophysiological and Biochemical Evaluations of Neuropathy Risk in Oral Levodopa versus Levodopa/Carbidopa Intestinal Gel Treatment". (PubMed, Arq Neuropsiquiatr) - No abstract available

Journal • Pain

Potential Vitamin B6 Depletion During Carbidopa/Levodopa Therapy in Parkinson's Disease: A Scoping Review of Direct Evidence. (PubMed, Cureus) - "Direct vitamin B6 testing, interpreted with laboratory-specific reference intervals and complementary nutritional, hematologic, and neurologic assessment, is better supported by the available evidence than reliance on homocysteine alone. Prospective exposure-resolved studies are required before route-specific risk or universal supplementation can be recommended."

Journal • Review • CNS Disorders • Epilepsy • Hematological Disorders • Movement Disorders • Pain • Parkinson's Disease

Effect of levodopa-carbidopa intestinal gel infusion on objective measures of daytime sleepiness and nocturnal sleep in Parkinson's disease. (PubMed, Rev Neurol (Paris)) - "LCIGI had no significant impact on objectively measured daytime sleepiness (MSLT) or PSG sleep parameters."

Journal • CNS Disorders • Excessive Daytime Sleepiness • Movement Disorders • Parkinson's Disease • Sleep Disorder

Parkinson's disease in the United Arab Emirates (UAE): Emirates Neurology Society consensus guidelines. (PubMed, Front Neurol) - "Consensus was achieved on 146 recommendations across eight domains: (1) mandatory adoption of MDS-2015 diagnostic criteria; (2) age-stratified pharmacologic algorithms with levodopa as first-line for older or cognitively vulnerable patients; (3) structured non-motor symptom management; (4) rehabilitation and UAE cultural lifestyle adaptations including Ramadan fasting management, DBS considerations in women, family-centered care, and multilingual practice; (5) advanced therapy referral using the 5-2-1 rule integrated with the Making Informed Decisions to Aid Timely Management of Parkinson's Disease (MANAGE-PD) tool, with five device-aided options (subcutaneous foslevodopa/foscarbidopa, apomorphine SC- subcutanous, LCIG- Levodopa Carbidopa Intestinal Gel, DBS- Deep Brain Stimulation, MRgFUS- MRI guided focussed ultrasound) presented through shared decision-making; (6) a three-tier service model; (7) UAE formulary mapping; and (8) center accreditation and registry..."

Clinical guideline • Journal • Review • CNS Disorders • Movement Disorders • Parkinson's Disease

Continuous subcutaneous foslevodopa/foscarbidopa in advanced Parkinson's disease: A clinical workflow from 50 consecutive patients at a single U.S. center. (PubMed, Clin Park Relat Disord) - "Median age was 68 years, disease duration 14 years, and baseline levodopa equivalent daily dose 1108 mg; 37 patients (74%) were male, 25 (50%) had prior DBS, and six (12%) had transitioned from levodopa-carbidopa intestinal gel. Among patients with DBS, median total stimulation current was 4.4 mA before and 4.0 mA after optimization; 7/25 (28%) had reductions. We describe a local clinical workflow used to implement LDp/CDp in routine care, including among patients with existing DBS."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Long-term real-world effectiveness of carbidopa/levodopa enteral suspension after 36 months of treatment initiation in advanced Parkinson's disease in the US: final results from the PROviDE study. (PubMed, Clin Park Relat Disord) - " Pursuing Real-World Outcomes via Duopa Ecosystem (PROviDE) was a 36-month prospective, observational study evaluating the effectiveness of CLES in patients with aPD in the US...A statistically significant improvement in PDQ-8 was observed as early as month 3 (-4.1, p = .001) with no worsening over time. Long-term treatment with CLES provides significant and clinically meaningful reduction in OFF-time, patient's treatment satisfaction, and maintained QoL in the real-world setting."

Journal • Real-world evidence • CNS Disorders • Movement Disorders • Parkinson's Disease

Multicenter Retrospective Study of LCIG Therapy in Japan: Efficacy, Factors Associated with Discontinuation, and Case-based Insights. (PubMed, Intern Med) - "Conclusion This study provides region-specific real-world insights into LCIG therapy. Together with lessons from five instructive cases, these findings may help optimize LCIG management in clinical settings."

Journal • Retrospective data • CNS Disorders • Movement Disorders • Parkinson's Disease • Psychiatry

Letter on: "Electrophysiological and Biochemical Evaluations of Neuropathy Risk in Oral Levodopa versus Levodopa/Carbidopa Intestinal Gel Treatment". (PubMed, Arq Neuropsiquiatr) - No abstract available

Journal • Pain

STN-DBS and LCIG differentially affect long-term axial symptoms in Parkinson's disease. (PubMed, NPJ Parkinsons Dis) - "Longitudinally, LCIG treatment was associated with lower odds of long-term axial deterioration compared with STN-DBS, after adjustment for baseline differences and levodopa equivalent daily dose, despite an increased risk of dyskinesias. A significant treatment-by-time interaction suggested more favourable long-term axial symptom trajectories in the LCIG group."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Continuous Intrajejunal Levodopa-Carbidopa Infusion in Parkinson's Disease Associated with 22q11.2 Deletion Syndrome: A Case Series. (PubMed, Mov Disord Clin Pract) - "LCIG may represent a valuable therapeutic option in selected patients with 22q11DS-associated Parkinson's disease when psychiatric comorbidity limits other advanced therapies."

Journal • CNS Disorders • Developmental Disorders • Genetic Disorders • Immunology • Mental Retardation • Movement Disorders • Parkinson's Disease • Primary Immunodeficiency • Psychiatry

Adverse event trajectories and treatment discontinuation in advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel. (PubMed, Parkinsonism Relat Disord) - "In real-world practice, single AE may follow different cumulative incidence trajectories, with device-related complications, hallucination and weight loss showing a progressive incidence over long follow-up. AEs related to treatment discontinuation occur in about one-fifth of the patients."

Adverse events • Journal • CNS Disorders • Movement Disorders • Pain • Parkinson's Disease

Beyond advanced therapies: sublingual apomorphine as rescue treatment for refractory freezing of gait in LCIG-treated Parkinson’s disease (EAN 2026) - "The second patient was a 59-year-old man with 14 years of disease duration, previously treated with continuous subcutaneous apomorphine infusion and currently on LCIG due to suboptimal motor control. Sublingual apomorphine may represent a useful and well-tolerated rescue option for refractory FoG in complex PD patients treated with LCIG. These cases suggest that rescue strategies using different dopaminergic mechanisms should also be considered in advanced disease stages."

Metastases • CNS Disorders • Movement Disorders • Parkinson's Disease

Long-term Global Survival Analysis from the Ferrara Registry of Device-Aided Therapies for Parkinson’s Disease (ReFerDAT Study) (EAN 2026) - " Clinical and demographic data of all patients who underwent DAT implantation (Deep Brain Stimulation (DBS) or Levodopa–Carbidopa Intestinal Gel (LCIG)) at the Advanced Therapies for Movement Disorders Clinic, Neurology Department of Ferrara, from 2000 to 2023, were retrospectively analysed and compared. Although causes of death differ between groups, overall long-term survival is comparable across DAT types. Age at implantation is the only factor exerting a stable long-term effect on survival, independent of device type."

Clinical • CNS Disorders • Infectious Disease • Movement Disorders • Parkinson's Disease

Levodopa/carbidopa intestinal gel infusion: Clinical indications and management (EAN 2026) - No abstract available

Clinical • CNS Disorders • Gene Therapies • Movement Disorders • Myelodysplastic Syndrome • Parkinson's Disease

Peripheral Nerve Safety of Continuous Subcutaneous Foslevodopa Infusion in Parkinson’s Disease: A Prospective Neurophysiological and Skin Biopsy Study (EAN 2026) - "Background and aims: Continuous dopaminergic infusion therapies are used in advanced Parkinson's disease (PD) to improve motor fluctuations; however, studies in patients treated with levodopa/carbidopa intestinal gel (LCIG) have reported peripheral neuropathies, including early small-fiber involvement [1,2]... In this cohort SC foslevodopa was not associated with incident or progressive large-fiber peripheral neuropathy over medium-term follow-up while skin biopsy revealed small-fiber involvement in a subset of patients. Whether this reflects dissociated fiber involvement or disease-related small-fiber denervation remains to be elucidated. Combined electrophysiological and morphological monitoring may improve the detection of early peripheral nerve involvement during infusion therapies."

Biopsy • Clinical • CNS Disorders • Movement Disorders • Parkinson's Disease

Complications of Levodopa–Carbidopa Intestinal Gel Therapy: Polyneuropathy, Cacosmia, and Peritonitis (EAN 2026) - No abstract available

L-Dopa/Carbidopa intestinal gel infusion in advanced Parkinson's disease: real-life mobility insights from wearable sensors. (PubMed, Front Neurol) - "This likely reflects more consistent motor control throughout the day due to continuous dopaminergic delivery. By detecting fluctuation-related motor impairment through variability metrics, wearable sensor technology may offer a valuable tool to enhance the clinical management of LCIG, supporting patient selection, medication titration, and the longitudinal monitoring of treatment efficacy and safety."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Percutaneous endoscopic gastrostomy with jejunal extension versus direct percutaneous endoscopic jejunostomy: patient-related outcomes and complications. (PubMed, Clin Endosc) - "Percutaneous endoscopic gastrostomy with jejunal extension (PEG-J) and direct percutaneous endoscopic jejunostomy (D-PEJ) are used for jejunal feeding or administration of levodopa-carbidopa intestinal gel in patients with Parkinson's disease...However, D-PEJ patients reported significantly more tube-related pain (44.4% vs. 15.9%). D-PEJ represents a viable alternative to PEG-J in experienced centers and should be considered when frequent complications with jejunal extensions occur."

Journal • CNS Disorders • Movement Disorders • Pain • Parkinson's Disease